Mumbai, August 3 (Udaipur Kiran): Dr. Reddy’s Laboratories is currently trading at Rs. 1414.40 on 29-Jun-2026 and a 52 week low of Rs. Dr. Reddy’s Laboratories has received approval from U.S. Food and Drug Administration (USFDA) for its rituximab biosimilar, a biosimilar to Rituxan (rituximab), for the U.S. market. The product was developed, manufactured and submitted for approval by Dr. Reddy’s Laboratories. Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India.